Differentiation between non-Hodgkin's lymphoma recurrence and second primary lymphoma by VDJ rearrangement analysis

被引:15
作者
Libra, M
De Re, V
Gasparotto, D
Gloghini, A
Marzotto, A
Milan, I
Tirelli, U
Stivala, F
Carbone, A
Boiocchi, M
机构
[1] Ctr Riferimento Oncol, Div Expt Oncol 1, I-33081 Aviano, Italy
[2] Univ Catania, Dept Biomed Sci, Clin Pathol & Mol Oncol Sect, I-95124 Catania, Italy
[3] Ctr Riferimento Oncol, Div Pathol, I-33081 Aviano, Italy
[4] Ctr Riferimento Oncol, Div Med Oncol A, I-33081 Aviano, Italy
关键词
non-Hodgkin's lymphoma; relapse; VDJ;
D O I
10.1046/j.1365-2141.2002.03655.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Relapses in non-Hodgkin's lymphomas (NHL) could be due to the reappearance of the initial neoplasm or new primary tumours. Discrimination between the two events would allow a more targeted therapeutic approach. VDJ rearrangement was used as marker of clonality in metachronous biopsy specimens from 10 patients with relapsed B-NHL. Complimentarity determining region 3 was amplified and sequenced. D-JH was identical in eight matched primary/secondary tumours, confirming the diagnosis of recurrence. In contrast, primary and secondary tumours in two patients were of different clonal origin. Our data indicate that VDJ analysis is a fundamental tool for identificaton of relapses in NHL.
引用
收藏
页码:809 / 812
页数:4
相关论文
共 13 条
[11]   High-grade transformation of low-grade non-Hodgkin's lymphomas: Mechanisms of tumor progression [J].
Matolcsy, A .
LEUKEMIA & LYMPHOMA, 1999, 34 (3-4) :251-259
[12]   Rituximab chimeric Anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:: Half of patients respond to a four-dose treatment program [J].
McLaughlin, P ;
Grillo-López, AJ ;
Link, BK ;
Levy, R ;
Czuczman, MS ;
Williams, ME ;
Heyman, MR ;
Bence-Bruckler, I ;
White, CA ;
Cabanillas, F ;
Jain, V ;
Ho, AD ;
Lister, J ;
Wey, K ;
Shen, D ;
Dallaire, BK .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2825-2833
[13]  
Shioyama Y, 2000, Radiat Med, V18, P369